US Congress House Bill 465 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Democrat 23-0)
Status: Introduced on January 10 2019 - 25% progression, died in committee
Action: 2019-01-25 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Prescription Drug Price Relief Act of 2019

Rep. Ro Khanna [D-CA]	Sen. Peter Welch [D-VT]	Rep. Elijah Cummings [D-MD]	Rep. Alexandria Ocasio-Cortez [D-NY]
Rep. Janice Schakowsky [D-IL]	Rep. Mark Pocan [D-WI]	Rep. Ilhan Omar [D-MN]	Rep. Rosa DeLauro [D-CT]
Rep. Joseph Neguse [D-CO]	Rep. Barbara Lee [D-CA]	Rep. Rashida Tlaib [D-MI]	Rep. Ayanna Pressley [D-MA]
Rep. Tulsi Gabbard [D-HI]	Rep. Peter DeFazio [D-OR]	Rep. Pramila Jayapal [D-WA]	Rep. Mark DeSaulnier [D-CA]
Rep. Eleanor Norton [D-DC]	Rep. Debra Haaland [D-NM]	Rep. Debbie Mucarsel-Powell [D-FL]	Rep. Danny Davis [D-IL]
Rep. Jamie Raskin [D-MD]	Rep. Lucille Roybal-Allard [D-CA]	Rep. Grace Meng [D-NY]

Date	Chamber	Action
2019-01-25	House	Referred to the Subcommittee on Health.
2019-01-10	House	Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
2019-01-10	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-01-10	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-01-10	House	Introduced in House

SB102 (Same As) 2019-01-10 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/house-bill/465/all-info
Text	https://www.congress.gov/116/bills/hr465/BILLS-116hr465ih.pdf